Pfizer Inc.

Recent Events

News & Analysis

pfizer inc. and stock - All News and Analysis

• Pfizer Stock Shrugs Off $2.3B Bextra Fine; Can Anything Deter Off-Label Promotion?

  BNET - 2009-09-08

  Pfizer's $2.3 billion settlement with the government over its mismarketing of Bextra is significant, but a look at other liabilities and settlements suggests that stock prices are unaffected by government discipline of off-label marketing. by Jim Edwards

  Tags: Pfizer Inc., Stock, Settlement, Government, Litigation, Vertical Industries, Investment, Business Operations, Finance, Jim Edwards

• Regis Philbin Says Pfizer's a Turkey: "Baloney the Dividend!"

  BNET - 2009-08-13

  Is it just me or did Regis Philbin call Pfizer stock a "turkey" on CNBC the other day? (See video below.) The Fast Money show had him on to ask him about his stocks, which are mostly in the tank, he admits. by Jim Edwards

  Tags: Pfizer Inc., Stock, Dividend, Turkey, Regis Philbin, Investment, Financial Planning, Personal Finance, Finance, Jim Edwards

• Pfizer Director Whose Stock Sold Ahead of Wyeth Merger: "I Sometimes Know Too Much''

  BNET - 2009-02-15

  What are we to make of the Bloomberg report that Pfizer director James Kilts sold $259,772 of his shares in the company around the same time Pfizer began negotations to acquire Wyeth? In acquisitions, the buying company's stock usually declines because its cash is being spent on...

  Tags: Wyeth, Merger, Pfizer Inc., Stock, Investment, Corporate Governance, Finance, Business Operations, Corporate Law, Jim Edwards

• Sanofi CEO Viehbacher Wants More Cuts; Drug Reps' Necks on the Block

  BNET - 2009-02-10

  Sanofi-Aventis's Q4 earnings call tomorrow could set the stage for a dramatic few days at the company, according to Bloomberg, as CEO Chris Viehbacher told analysts and his staff that Sanofi needs to cut operating costs and possibly buy a small or midsize firm. Viehbacher wants to get $1.3 billion...

  Tags: Revenue, Layoff, Pfizer Inc., Stock, Bloomberg L.P., CEO, Sanofi, Operational Accounting, Workforce Management, Finance, Human Resources, Jim Edwards

• Reaction to Pfizer-Wyeth: Employees Despair, Plot Rebellion; Analysts Shrug; PFE Stock Down 10%

  BNET - 2009-01-26

  Reaction to the Pfizer-Wyeth merger is ... mixed, to say the least. Pfizer employees think this will be Pharmacia/Warner-Lambert redux. Wall Street analysts are all over the place. Pfizer's stock has lost 10 percent of its value between the opening bell and lunchtime. Wyeth's...

  Tags: Wyeth, Merger, Pfizer Inc., Stock, Kindler, Mergers & Acquisitions, Investment, Finance, Jim Edwards

• Zacks Analyst Blog Highlights: Peabody Energy Corp., Pfizer Inc., SanDisk Corp., Everest Re Group, Ltd. and Biogen Idec Inc

  - 2008-10-23

  CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Peabody Energy Corp. (NYSE: BTU), Pfizer Inc. (NYSE: PFE), SanDisk Corp....

  Tags: Biogen Idec Inc., blog, FINANCE, Investment, MARKETING, Nasdaq Stock Market Inc., newsletter, NYSE Euronext, Peabody Energy Corp., Pfizer Inc., SanDisk Corp., stock

• Zacks Analyst Blog Highlights: Cemex S.A. de C.V., Baxter International Inc., Web.com, Gilead Sciences, Inc. and Pfizer Inc

  - 2008-10-21

  CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Cemex S.A. de C.V. (NYSE: CX), Baxter International Inc. (NYSE: BAX),...

  Tags: Baxter International Inc., blog, FINANCE, Gilead Sciences Inc., Investment, MARKETING, Nasdaq Stock Market Inc., newsletter, NYSE Euronext, Pfizer Inc., stock

• With Buybacks, J&J, Abbott, and Pfizer All See the Same Thing: Cheap Stock

  BNET - 2008-10-13

  Abbott Labs announced a $5 billion stock buyback plan Monday. Such plans are often used by companies seeking to prop up stock that’s down for a good reason, i.e. the company sucks. But in a market like this one, where everyone is down at bizarre lows, suddenly those buybacks look...

  Tags: Johnson & Johnson, Pfizer Inc., Stock, Investment, Finance, Jim Edwards

• Barron's: Only Pfizer and Merck Are Cash Havens

  BNET - 2008-10-13

  Of 25 stocks identified by Barron's as being "Like Money in the Bank," only two are pharma companies -- Merck and Pfizer. That should comes as a disappointment to the business, which has traditionally regarded itself as a sort of cash-rich safety play for stock holders. The...

  Tags: Roche Holding AG, Pfizer Inc., Stock, Merck & Co. Inc., Barron, List*, Investment, Finance, Jim Edwards

• Is Pfizer's Sleeping Pill Obsession Running up King Stock?

  - 2008-08-07

  Is Pfizer's Sleeping Pill Obsession Running up King Stock?RE: Is Pfizer's Sleeping Pill Obsession Running up King Stock?Sonata went generic earlier this summer...

  Tags: Investment, King Stock, Pfizer Inc., stock